Emma Shtivelman, PhD Cancer Commons Chief Scientist
-
July 6, 2017
ASCO 2017: Breast Cancer Treatment News
Emma Shtivelman, PhDLast month, the annual American Society of Clinical Oncology (ASCO) meeting took place in Chicago. Thousands of oncologists, patients, and journalists gathered to learn about the most recent developments in cancer research and treatment. Here are some breast cancer highlights from the meeting: Triple negative breast cancer (TNBC) is considered more responsive to treatment with immune checkpoint drugs than any other type of breast cancer.… Read more »
-
May 31, 2017
The Trouble With KRAS
Emma Shtivelman, PhDMutations in the gene that encodes the KRAS protein are frequently encountered in various human cancers. They are found in about 30% of non-small cell lung cancers (NSCLCs), making KRAS the single most common gene mutated in this cancer. The rate of KRAS mutations in other cancers, such as pancreatic or colorectal, is even higher. A mutant KRAS protein that is always in the… Read more »
-
April 4, 2017
Metastatic Melanoma: Not Quite Curable…But Getting There
Emma Shtivelman, PhDBy 2050, the number of deaths due to malignant melanoma in the U.S. could be three times lower than peak levels reached before 1960. Researchers presented the data behind this prediction at the 2017 European Cancer Congress in January. It is unclear how much of this anticipated decline in deaths can be attributed to the availability of new, effective treatments. However, it is obvious… Read more »
-
March 7, 2017
Clinical Trials Test Treatments for High-Grade Brain Tumors
Emma Shtivelman, PhDWith a few exceptions, glioblastoma (GBM) remains largely incurable, and the U.S. Food and Drug Administration (FDA) has approved few treatments for the disease. Surgery (when feasible), radiation, and temozolomide are used in most patients. But even if a newly diagnosed tumor can be surgically excised, recurrences are too common. In this blog post, I simply list some of the new treatments available in… Read more »
-
February 7, 2017
Testing for Tumor Mutations: Liquid Biopsy Versus Traditional Biopsy
Emma Shtivelman, PhDUpdate as of August 27, 2020: A lot has changed in the three-and-a-half years since this blog post was written. Liquid biopsies are by now widely recognized and used as a valuable diagnostic and monitoring tool. Many of the reservations and concerns described in the original post below have been addressed and largely resolved by refining the technology. The latest proof of this is… Read more »
-
January 17, 2017
In Metastatic Breast Cancer Treatment, Not All CDK Inhibitors Are Equal
Emma Shtivelman, PhDDoctors prescribe drugs known as CDK inhibitors to treat some women with estrogen-receptor-positive (ER+) metastatic breast cancer. Research into these drugs is ongoing, and new, promising CDK inhibitor options are on the horizon. Here, I address the current outlook for CDK inhibitors in ER+ breast cancer. First, some background: ER+ breast cancers comprise about 70% of all breast cancers. The name reflects the fact… Read more »
-
November 10, 2016
War of the Checkpoint Inhibitors: Anti-PD-1 Drugs Move into First-Line Treatment in NSCLC
Emma Shtivelman, PhDLast year, the U.S. Food and Drug Administration (FDA) approved two anti-PD-1 checkpoint inhibitors, a type of immunotherapy, for treatment of non-small cell lung cancer (NSCLC) in patients whose cancer has progressed after first-line treatment with chemotherapy. Now, the manufacturers of both drugs, pembrolizumab (made by Merck) and nivolumab (made by Bristol-Myers Squibb; BMS) are intent on expanding the indications for use of their… Read more »
-
August 15, 2016
Melanoma: New Drugs and New Challenges (Part 2 of 2)
Emma Shtivelman, PhDAs always, the more new treatments become available in melanoma, the more new challenges arise. With eight new drugs approved for melanoma in the last five years, oncologists may sometimes face the difficult choice of what drugs to choose for a patient’s first-line treatment. Immune checkpoint drugs sometimes cause serious side effects, but progress is being made on how to treat these and also how to treat patients with pre-existing autoimmune conditions. New approaches are needed in efforts to prevent recurrence of melanomas diagnosed at earlier stages of disease progression.
-
August 8, 2016
Melanoma: New Drugs and New Challenges (Part 1 of 2)
Emma Shtivelman, PhDNew targeted and immunotherapy drugs have changed the diagnosis of metastatic melanoma from a death sentence into a disease that can potentially be managed and even cured. Nevertheless, these new drugs do not work in all patients, or they may stop working after a transient response. This post (part one of two) will describe ongoing efforts to find drug combinations with higher efficacy than single drugs and decipher the mechanisms underlying drug resistance.
-
July 12, 2016
New Research on Triple Negative Breast Cancer Emerges at ASCO 2016
Emma Shtivelman, PhDThe American Society of Clinical Oncology (ASCO) meeting of 2016 is behind us, but oncologists, patients, and journalists are still analyzing the most interesting presentations made there. Below, we describe some of the more prominent results in triple negative breast cancer (TNBC), both promising and disappointing.